GEN Exclusives

More »

GEN News Highlights

More »
Mar 2, 2009

Novartis to Kick Off R&D Alliance with Epistem with $4M

  • Epistem entered an R&D collaboration with Novartis to identify new drug targets and therapeutics across a variety of disease areas. Novartis will pay $4 million up front and provide research funding for two years.

    Epistem will also receive a license fee and up to $45 million in milestones for each target Novartis gains rights to. Additionally, Novartis will pay tiered royalties.

    The collaboration combines Epistem's stem cell expertise and drug discovery program with Novartis' insights into disease pathways and bioinformatics. Novartis has an option to exclusively license targets for development of biotherapeutic products.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should “Special K” Get Special Treatment?

In the near term, what is the best way to use ketamine in treating depression?